the European Haemophilia Consortium and the National Hemophilia Foundation said Sanofi had voluntary put the full development programme on hold “due to the identification of new adverse events”.

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Sanofi and Sobi's haemophilia partnership has been under competitive pressure from new therapies like Roche's antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Sanofi to buy US biopharma group Blueprint for up to $9.5 billion France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare ...